nejm glp 1 Expanding Clinical Benefits for GLP-1–Receptor Agonists Discovery of GLP-1–Based Drugs for

With ongoing research into their benefits across cardiovascular, neurological, hepatic, gastrointestinal, and renal systems, GLP-1 receptor agonists are at the forefront of personalized and integrative care

Case example : A patient receives glucose

Barr, D

A 2015 study by Huang and colleagues in Drug Design, Development and Therapy used a rat alkali-burn model (n=10 per group) and HUVECs treated with BPC-157 at 200800 ng/mL, reporting accelerated wound closure with enhanced granulation tissue, reepithelialization, and dermal remodeling by day 18, alongside increased endothelial migration and vascular tube formation in vitro via ERK1/2 phosphorylation though the abstract does not report numeric % wound closure or p-values

All findings are supported with extensive citations from academic studies, industry reports, and recent news

Game changed for me